Literature DB >> 28634883

A Minimal Continuous-Time Markov Pharmacometric Model.

Emilie Schindler1, Mats O Karlsson2.   

Abstract

In this work, an alternative model to discrete-time Markov model (DTMM) or standard continuous-time Markov model (CTMM) for analyzing ordered categorical data with Markov properties is presented: the minimal CTMM (mCTMM). Through a CTMM reparameterization and under the assumption that the transition rate between two consecutive states is independent on the state, the Markov property is expressed through a single parameter, the mean equilibration time, and the steady-state probabilities are described by a proportional odds (PO) model. The mCTMM performance was evaluated and compared to the PO model (ignoring Markov features) and to published Markov models using three real data examples: the four-state fatigue and hand-foot syndrome data in cancer patients initially described by DTMM and the 11-state Likert pain score data in diabetic patients previously analyzed with a count model including Markovian transition probability inflation. The mCTMM better described the data than the PO model, and adequately predicted the average number of transitions per patient and the maximum achieved scores in all examples. As expected, mCTMM could not describe the data as well as more flexible DTMM but required fewer estimated parameters. The mCTMM better fitted Likert data than the count model. The mCTMM enables to explore the effect of potential predictive factors such as drug exposure and covariates, on ordered categorical data, while accounting for Markov features, in cases where DTMM and/or standard CTMM is not applicable or conveniently implemented, e.g., non-uniform time intervals between observations or large number of categories.

Entities:  

Keywords:  NONMEM; non-linear mixed effects models; ordered categorical data; pharmacokinetic-pharmacodynamic; serial correlations

Mesh:

Year:  2017        PMID: 28634883     DOI: 10.1208/s12248-017-0109-1

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  18 in total

1.  A mechanism-based approach for absorption modeling: the Gastro-Intestinal Transit Time (GITT) model.

Authors:  Emilie Hénin; Martin Bergstrand; Joseph F Standing; Mats O Karlsson
Journal:  AAPS J       Date:  2012-06       Impact factor: 4.009

2.  A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations.

Authors:  Martin Bergstrand; Erik Söderlind; Ulf G Eriksson; Werner Weitschies; Mats O Karlsson
Journal:  Pharm Res       Date:  2011-09-23       Impact factor: 4.200

3.  Comparison of proportional and differential odds models for mixed-effects analysis of categorical data.

Authors:  Maria C Kjellsson; Per-Henrik Zingmark; E Niclas Jonsson; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-09-23       Impact factor: 2.745

4.  Transition modeling of neuropsychiatric impairment in HIV.

Authors:  Kuteesa R Bisaso; Jackson K Mukonzo; Ene I Ette
Journal:  Comput Biol Med       Date:  2016-04-15       Impact factor: 4.589

5.  Likert pain score modeling: a Markov integer model and an autoregressive continuous model.

Authors:  E L Plan; J-P Elshoff; A Stockis; M L Sargentini-Maier; M O Karlsson
Journal:  Clin Pharmacol Ther       Date:  2012-03-21       Impact factor: 6.875

6.  A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.

Authors:  Ron J Keizer; Anubha Gupta; Melvin R Mac Gillavry; Mendel Jansen; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Mats O Karlsson; Alwin D R Huitema
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-07-23       Impact factor: 2.745

7.  A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data.

Authors:  L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1994-09       Impact factor: 6.875

8.  Pharmacokinetic-pharmacodynamic modeling of severity levels of extrapyramidal side effects with markov elements.

Authors:  V Pilla Reddy; K J Petersson; A A Suleiman; A Vermeulen; J H Proost; L E Friberg
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

9.  Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Authors:  Per-Henrik Zingmark; Matts Kågedal; Mats O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-11-07       Impact factor: 2.410

10.  PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST.

Authors:  E K Hansson; G Ma; M A Amantea; J French; P A Milligan; L E Friberg; M O Karlsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-12-04
View more
  7 in total

1.  Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial.

Authors:  Carolina Llanos-Paez; Claire Ambery; Shuying Yang; Maggie Tabberer; Misba Beerahee; Elodie L Plan; Mats O Karlsson
Journal:  AAPS J       Date:  2021-06-02       Impact factor: 4.009

2.  PK/PD modeling links accelerated resolution of COVID-19-related clinical symptoms to SARS-CoV-2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together.

Authors:  C Steven Ernest; Jenny Y Chien; Dipak R Patel; Emmanuel Chigutsa
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-04-05

3.  A Bounded Integer Model for Rating and Composite Scale Data.

Authors:  Gustaf J Wellhagen; Maria C Kjellsson; Mats O Karlsson
Journal:  AAPS J       Date:  2019-06-06       Impact factor: 4.009

4.  A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients.

Authors:  Eva Germovsek; Claire Ambery; Shuying Yang; Misba Beerahee; Mats O Karlsson; Elodie L Plan
Journal:  AAPS J       Date:  2019-04-26       Impact factor: 4.009

5.  Analysis of Longitudinal-Ordered Categorical Data for Muscle Spasm Adverse Event of Vismodegib: Comparison Between Different Pharmacometric Models.

Authors:  Tong Lu; Yujie Yang; Jin Y Jin; Matts Kågedal
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-01-30

6.  Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach.

Authors:  Eduard Schmulenson; Linda Krolop; Sven Simons; Susanne Ringsdorf; Yon-Dschun Ko; Ulrich Jaehde
Journal:  Cancer Chemother Pharmacol       Date:  2020-08-27       Impact factor: 3.333

7.  A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation.

Authors:  Jie Zhou; Laura Curd; Lauren R L Lohmer; Natalie Delpratt; Joachim Ossig; Frank Schippers; Thomas Stoehr; Virginia D Schmith
Journal:  Clin Transl Sci       Date:  2021-04-09       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.